Christopher LaGanke - Concepedia

Author

Christopher LaGanke

Also Known As

C. C. LaGanke, C.C. LaGanke, Christopher C LaGanke, Christopher C. LaGanke, Christopher C. Laganke, Christopher LaGanke, Christopher Laganke, Lauren Krupp, Mark Cascione, Stanley J. Krolczyk

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

NeuroRx Research (Canada)Biogen (United States)McGill University Urology Associates Montreal Neurological Institute and Hospital

About

Christopher LaGanke is an author at NeuroRx Research (Canada) specializing in multiple sclerosis, medicine, and neuroimmunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	544
2	Neurology	4	4	531
3	Public Health	1	1	13
4	Clinical Nutrition	1	1	13
5	Immunology	1	1	13

Christopher LaGanke

Publications

910

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch, The Lancet Neurology Neurological DisorderPhase 2BClinical TrialsPlacebo-controlled TrialPharmacotherapy	2021	177
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial Diego Cadavid, Michelle Mellion, Raymond Hupperts, The Lancet Neurology Neurological DisorderClinical NeurologyClinical TrialsNeurological ProgressNeurology	2019	173
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS Robert J. Fox, Andrew Chan, Ralf Gold, Neurology Clinical Practice	2016	104
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial John Foley, Gilles Defer, Lana Zhovtis Ryerson, The Lancet Neurology Relapsing-remitting Multiple SclerosisClinical NeurologyClinical TrialsNeurological ProgressTreatment Option	2022	103
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, The Lancet Neurology Neurological DisorderMedicinePaediatric Multiple SclerosisPediatricsPlacebo-controlled Trial	2021	78
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study Robert T. Naismith, Jerry S. Wolinsky, Annette Wundes, Multiple Sclerosis Journal	2019	62
Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial Christopher LaGanke, Lawrence Samkoff, Keith R. Edwards, Neurology Neuroimmunology & Neuroinflammation	2017	58
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Tjalf Ziemssen, Ann Bass, Regina Berkovich, CNS Drugs	2020	55
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management Adam Cuker, Ann Bass, Čongor Nadj, Multiple Sclerosis Journal	2019	54
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study B. Singer, Douglas L. Arnold, Jelena Drulović, Multiple Sclerosis Journal	2023	22

Page 1